Tadashi Nagakura

569 total citations
16 papers, 481 citations indexed

About

Tadashi Nagakura is a scholar working on Endocrinology, Diabetes and Metabolism, Oncology and Surgery. According to data from OpenAlex, Tadashi Nagakura has authored 16 papers receiving a total of 481 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Endocrinology, Diabetes and Metabolism, 8 papers in Oncology and 6 papers in Surgery. Recurrent topics in Tadashi Nagakura's work include Diabetes Treatment and Management (11 papers), Peptidase Inhibition and Analysis (8 papers) and Neuropeptides and Animal Physiology (6 papers). Tadashi Nagakura is often cited by papers focused on Diabetes Treatment and Management (11 papers), Peptidase Inhibition and Analysis (8 papers) and Neuropeptides and Animal Physiology (6 papers). Tadashi Nagakura collaborates with scholars based in Japan. Tadashi Nagakura's co-authors include Nobuyuki Yasuda, Kazuto Yamazaki, Isao Tanaka, Takashi Inoue, T. Saeki, Kazunobu Kira, Osamu Asano, Seiji Yoshikawa, Richard J. Clark and Osamu Takenaka and has published in prestigious journals such as Nature Communications, Biochemical and Biophysical Research Communications and Journal of Pharmacology and Experimental Therapeutics.

In The Last Decade

Tadashi Nagakura

16 papers receiving 468 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Tadashi Nagakura Japan 12 334 203 164 152 144 16 481
Daisho Hirota Japan 6 327 1.0× 77 0.4× 130 0.8× 162 1.1× 52 0.4× 6 519
Kasper Aaboe Denmark 8 486 1.5× 61 0.3× 182 1.1× 274 1.8× 66 0.5× 12 565
Stefan Tschopp Switzerland 4 321 1.0× 78 0.4× 297 1.8× 143 0.9× 26 0.2× 7 584
Lene Jensen Denmark 9 722 2.2× 62 0.3× 459 2.8× 330 2.2× 71 0.5× 11 846
Audrey Helleboid‐Chapman France 9 121 0.4× 91 0.4× 168 1.0× 140 0.9× 43 0.3× 11 377
Yasutaka Takeda Japan 9 231 0.7× 35 0.2× 171 1.0× 181 1.2× 36 0.3× 20 454
R. Cereda Italy 10 48 0.1× 101 0.5× 192 1.2× 92 0.6× 148 1.0× 15 470
M. Dodson Michael United States 13 285 0.9× 85 0.4× 212 1.3× 293 1.9× 33 0.2× 19 592
Hidemitsu Sakagami Japan 8 206 0.6× 42 0.2× 206 1.3× 182 1.2× 28 0.2× 13 515
Bernice Ellis United States 7 313 0.9× 24 0.1× 233 1.4× 158 1.0× 45 0.3× 10 434

Countries citing papers authored by Tadashi Nagakura

Since Specialization
Citations

This map shows the geographic impact of Tadashi Nagakura's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tadashi Nagakura with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tadashi Nagakura more than expected).

Fields of papers citing papers by Tadashi Nagakura

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tadashi Nagakura. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tadashi Nagakura. The network helps show where Tadashi Nagakura may publish in the future.

Co-authorship network of co-authors of Tadashi Nagakura

This figure shows the co-authorship network connecting the top 25 collaborators of Tadashi Nagakura. A scholar is included among the top collaborators of Tadashi Nagakura based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tadashi Nagakura. Tadashi Nagakura is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
Nishibata, Yuka, Mai Taniguchi, Ryo Nishiyama, et al.. (2024). Cathepsin C inhibition reduces neutrophil serine protease activity and improves activated neutrophil-mediated disorders. Nature Communications. 15(1). 6519–6519. 12 indexed citations
2.
Nagakura, Tadashi, et al.. (2018). Novel imaging-based assay system detecting delayed inhibitory effect on hERG channel using human iPS-derived cardiomyocytes. Journal of Pharmacological and Toxicological Methods. 93. 117–118. 1 indexed citations
3.
4.
Yamazaki, Kazuto, Takashi Inoue, Nobuyuki Yasuda, et al.. (2007). Comparison of Efficacies of a Dipeptidyl Peptidase IV Inhibitor and α-Glucosidase Inhibitors in Oral Carbohydrate and Meal Tolerance Tests and the Effects of Their Combination in Mice. Journal of Pharmacological Sciences. 104(1). 29–38. 25 indexed citations
5.
Yamazaki, Kazuto, Nobuyuki Yasuda, Takashi Inoue, et al.. (2006). 7-But-2-ynyl-9-(6-methoxy-pyridin-3-yl)-6-piperazin-1-yl-7,9-dihydro-purin-8-one Is a Novel Competitive and Selective Inhibitor of Dipeptidyl Peptidase IV with an Antihyperglycemic Activity. Journal of Pharmacology and Experimental Therapeutics. 319(3). 1253–1257. 12 indexed citations
6.
Yamazaki, Kazuto, Nobuyuki Yasuda, Takashi Inoue, et al.. (2006). Effects of the Combination of a Dipeptidyl Peptidase IV Inhibitor and an Insulin Secretagogue on Glucose and Insulin Levels in Mice and Rats. Journal of Pharmacology and Experimental Therapeutics. 320(2). 738–746. 14 indexed citations
7.
Yasuda, Nobuyuki, Tadashi Nagakura, Takashi Inoue, et al.. (2006). E3024, 3-but-2-ynyl-5-methyl-2-piperazin-1-yl-3,5-dihydro-4H-imidazo[4,5-d]pyridazin-4-one tosylate, is a novel, selective and competitive dipeptidyl peptidase-IV inhibitor. European Journal of Pharmacology. 548(1-3). 181–187. 16 indexed citations
8.
Yasuda, Nobuyuki, Kazuto Yamazaki, Takashi Inoue, & Tadashi Nagakura. (2005). Therapeutic potential of DPP-IV inhibitor for the treatment of Type 2 diabetes. Folia Pharmacologica Japonica. 125(6). 379–384. 1 indexed citations
9.
Yasuda, Nobuyuki, Takashi Inoue, Tadashi Nagakura, et al.. (2004). Metformin Causes Reduction of Food Intake and Body Weight Gain and Improvement of Glucose Intolerance in Combination with Dipeptidyl Peptidase IV Inhibitor in Zucker fa/fa Rats. Journal of Pharmacology and Experimental Therapeutics. 310(2). 614–619. 53 indexed citations
10.
Yamazaki, Kazuto, Nobuyuki Yasuda, Takashi Inoue, et al.. (2004). The combination of metformin and a dipeptidyl peptidase IV inhibitor prevents 5-fluorouracil-induced reduction of small intestine weight. European Journal of Pharmacology. 488(1-3). 213–218. 23 indexed citations
11.
Nagakura, Tadashi, et al.. (2003). Enteroinsular axis of db/db mice and efficacy of dipeptidyl peptidase IV inhibition. Metabolism. 52(1). 81–86. 48 indexed citations
12.
Yasuda, Nobuyuki, Tadashi Nagakura, Kazuto Yamazaki, Takashi Inoue, & Isao Tanaka. (2002). Improvement of high fat-diet-induced insulin resistance in dipeptidyl peptidase IV-deficient Fischer rats. Life Sciences. 71(2). 227–238. 45 indexed citations
13.
Yasuda, Nobuyuki, Takashi Inoue, Tadashi Nagakura, et al.. (2002). Enhanced secretion of glucagon-like peptide 1 by biguanide compounds. Biochemical and Biophysical Research Communications. 298(5). 779–784. 119 indexed citations
14.
Nagakura, Tadashi, Nobuyuki Yasuda, Kazuto Yamazaki, et al.. (2001). Improved Glucose Tolerance via Enhanced Glucose-Dependent Insulin Secretion in Dipeptidyl Peptidase IV-Deficient Fischer Rats. Biochemical and Biophysical Research Communications. 284(2). 501–506. 81 indexed citations
15.
Kamata, Satoshi, et al.. (2000). Vasorelaxant effect of a phosphodiesterase 3 inhibitor, olprinone, on isolated human radial artery. European Journal of Pharmacology. 396(1). 43–47. 12 indexed citations
16.
Shin, Yongchol, Ken Sawada, Tadashi Nagakura, et al.. (1996). Reconstitution of the F1-ATPase activity from purified α, β γ and δ or ϵ subunits with glutathione S-transferase fused at their amino termini. Biochimica et Biophysica Acta (BBA) - Bioenergetics. 1273(1). 62–70. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Daisho Hirota Breakdown of academic impact, for papers by Kasper Aaboe Breakdown of academic impact, for papers by Stefan Tschopp Breakdown of academic impact, for papers by Lene Jensen Breakdown of academic impact, for papers by Audrey Helleboid‐Chapman Breakdown of academic impact, for papers by Yasutaka Takeda Breakdown of academic impact, for papers by R. Cereda Breakdown of academic impact, for papers by M. Dodson Michael Breakdown of academic impact, for papers by Hidemitsu Sakagami Breakdown of academic impact, for papers by Bernice Ellis
Rankless by CCL
2026